Advertisement
News
Subscribe to MDT Magazine News

Reportlinker Adds The Drug Delivery Device Market Outlook to 2015

January 25, 2011 6:35 am | by Bio-Medicine.Org | Comments

NEW YORK, Jan. 25, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: The Drug Delivery Device Market Outlook to 2015 http://www.reportlinker.com/p0363596/The-Drug-Delivery-Device-Market-Outlook-to-2015.html Drug delivery device...

TOPICS:

If Hospitals Want a Competitive Advantage - Use Brain Monitors in Surgeries Requiring Sedation says Renowned Anesthesiologist

January 25, 2011 6:33 am | by Bio-Medicine.Org | Comments

NEWPORT BEACH, Calif., Jan. 25, 2011 /- Every business needs a competitive advantage over its rivals. Some use a cost advantage; others use a differentiation advantage. Hospitals are not immune from the constant struggle to attract and retain patients and doctors. Dr. Barry Friedberg says...

TOPICS:

R & J Public Relations Named Agency of Record for Aerocrine, Inc.

January 25, 2011 6:33 am | by Bio-Medicine.Org | Comments

BRIDGEWATER, N.J., Jan. 25, 2011 /- Aerocrine, Inc., an innovative medical technology company focused on the treatment of patients with inflamed airways, has selected R&J Public Relations, LLC of Bridgewater, N.J., as its public relations agency of record.  R&J will conduct...

TOPICS:
Advertisement

Reportlinker Adds The 2011 Clinical Chemistry Market: US, Europe, Japan

January 25, 2011 6:33 am | by Bio-Medicine.Org | Comments

NEW YORK, Jan. 25, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: The 2011 Clinical Chemistry Market: US, Europe, Japan http://www.reportlinker.com/p0365400/The-2011-Clinical-Chemistry-Market-US-Europe-Japan.html During the next decade,...

TOPICS:

Quest board boosts share repurchase authorization

January 25, 2011 4:45 am | by The Associated Press | Comments

Medical laboratory operator Quest Diagnostics Inc. said Tuesday its board of directors increased its share repurchase authorization by $750 million to $1 billion.The Madison, N.J., company had 171 million shares outstanding as of Dec. 31. Last year, it repurchased about 15 million shares for...

EASTEC to Foster Growth, Technology and Innovation for East Coast Manufacturers

January 25, 2011 4:33 am | by Society of Manufacturing Engineers | Comments

WEST SPRINGFIELD, MA, January 25, 2011 — According to the Institute for Supply Management, the largest supply management association in the world, manufacturers can expect more good news in 2011. The organization released its December 2010 Manufacturing ISM Report On Business®...

Materials for the January 27-28, 2011 Neurological Devices Panel Meeting

January 25, 2011 4:32 am | by U.S. Food & Drug Administration | Comments

Added Agenda, Roster, Questions, and FDA Executive Summary.

Frost & Sullivan Recognizes Cohera Medical, Inc.® for Developing TissuGlu®, Its Pioneering Surgical Adhesive That Is Strong, Easy-To-Use, Biocompatible and Resorbable

January 25, 2011 4:31 am | by Bio-Medicine.Org | Comments

MOUNTAIN VIEW, Calif., Jan. 25, 2011 /- Based on its recent analysis of the surgical adhesives market, Frost & Sullivan recognizes Cohera Medical, Inc. with the 2010 Frost & Sullivan Award for New Product Innovation of the Year Award for TissuGlu. With surgeons looking for better...

TOPICS:
Advertisement

Savient Pharmaceuticals Names John H. Johnson Chief Executive Officer

January 25, 2011 3:37 am | by Bio-Medicine.Org | Comments

EAST BRUNSWICK, N.J., Jan. 25, 2011 /- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) today announced that its board of directors has named John H. Johnson as Chief Executive Officer, effective January 31, 2011.  Mr. Johnson will also serve as a member of Savient's board of directors....

TOPICS:

PDL BioPharma Appoints Caroline Krumel as Vice President of Finance and Thanks Karen Wilson for her Contributions

January 25, 2011 3:37 am | by Bio-Medicine.Org | Comments

INCLINE VILLAGE, Nev., Jan. 25, 2011 /- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced the appointment of Caroline Krumel, CPA to the position of vice president of finance and chief accounting officer, effective January 31, 2011. Ms. Krumel will replace Karen Wilson, who is...

TOPICS:

Angelini Labopharm Confirms Appointment of Mary Anne Heino as President

January 25, 2011 3:37 am | by Bio-Medicine.Org | Comments

PRINCETON, N.J., Jan. 25, 2011 /- Angelini Labopharm, LLC, today confirmed Mary Anne Heino's appointment as President of the Company.  Formerly Senior Vice President, Sales and Marketing for Labopharm Inc. and President of the company's wholly owned subsidiary, Labopharm USA, Inc.,...

TOPICS:

Codexis Signs First Japanese Biocatalysis Collaboration With Dainippon Sumitomo Pharma

January 25, 2011 3:37 am | by Bio-Medicine.Org | Comments

REDWOOD CITY, Calif., Jan. 25, 2011 /- Codexis, Inc. (Nasdaq: CDXS ) today announced the company's first biocatalysis collaboration in Japan, with Dainippon Sumitomo Pharma Co., Ltd. (DSP), one of the ten largest Japanese pharmaceutical manufacturers. Under the agreement, Codexis will...

TOPICS:

AndroScience Corporation Awarded a $3.8 Million, 3-Year Milestone-Driven, Cooperative Translational Research Grant from the NIH to Develop an Oral Treatment for Spinal Bulbar ...

January 25, 2011 3:35 am | by Bio-Medicine.Org | Comments

SAN DIEGO, Jan. 25, 2011 /- AndroScience Corp. (ASC), based in San Diego, California, announced receiving a $3.8 Million, 3-year milestone-driven, cooperative translational research grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes...

TOPICS:

Chopin's hallucinations were probably caused by epilepsy

January 25, 2011 3:34 am | by EurekAlert | Comments

(BMJ-British Medical Journal) The composer Frederic Chopin, who regularly hallucinated, probably had temporal lobe epilepsy throughout his short life, reveals research published online in Medical Humanities. Hallucinations typically feature in seizure disorders, they say.

TOPICS:

Mylan Announces Caduet® Settlement Agreement

January 25, 2011 3:33 am | by Bio-Medicine.Org | Comments

PITTSBURGH, Jan. 25, 2011 /- Mylan Inc. (Nasdaq: MYL ) today announced that it has entered into a settlement agreement with Pfizer Inc. resolving litigation related to Caduet® Tablets, 2.5 mg/10, 2.5 mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 5 mg/80 mg, 10 mg/10 mg,...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading